GET DAILY SIGNALSMediWound (MDWD) Q3 2026: Revenue Shortfall Widens Losses Amid Clinical Progress
Key Takeaways
- MediWound reported third-quarter 2026 revenue of $3.6 million, down about 33% from $5.4 million a year earlier and well below consensus estimates near $6.7–$6.9 million.
- The net loss widened to $6.0 million, or $0.47 per share, from $2.7 million, or $0.24 per share, in the prior-year quarter, as research and development spending climbed 77% year over year.
- On an adjusted basis, the loss per share of $0.65 modestly beat analyst expectations of roughly $0.66–$0.72, though the top-line shortfall drove the market's negative reaction.
- Gross margin improved sharply to 28.5% from 16.5%, reflecting a higher mix of royalty revenue, while management reiterated that NexoBrid sales remain constrained by supply rather than demand.
- The company's Phase III VALUE trial for EscharEx remains on track, with enrollment completion targeted for the end of the first quarter of 2027 and top-line data expected in mid-2027.
Earnings Context and Why It Matters
MediWound's third-quarter report arrives at an important juncture for the Israeli biopharmaceutical company focused on enzymatic therapeutics for tissue repair. The business carries significant exposure to development services for U.S. government programs, so its revenue path often hinges more on funding decisions than on pure commercial traction. From what I see, the quarter highlights two counterbalancing dynamics: near-term pressure from rising research outlays and the longer-term potential tied to EscharEx, the late-stage candidate aimed at chronic wounds. With cash levels declining and a public offering completed in November, the update also clarifies the balance-sheet runway ahead of a key clinical readout.
Reported Results
For the third quarter ended September 30, 2026, MDWD posted revenue of $3.6 million, a decline of roughly 33% from $5.4 million in the same period a year earlier. The drop stemmed mainly from lower revenue tied to development services for U.S. government programs. Gross profit edged up slightly to $1.0 million, pushing gross margin to 28.5% from 16.5%, thanks to a larger share of royalty revenue.
The net loss expanded to $6.0 million, or $0.47 per share, from $2.7 million, or $0.24 per share, in the prior-year quarter. Research and development expenses rose to $6.2 million from $3.5 million, reflecting stepped-up investment in the Phase III VALUE trial for EscharEx. On an adjusted basis, the loss per share of $0.65 came in a touch better than consensus estimates of roughly $0.66 to $0.72, while revenue of $3.57 million fell well short of the consensus range of about $6.7–$6.9 million. Operating loss widened to $8.5 million from $6.5 million, and adjusted EBITDA loss reached $7.4 million versus $5.4 million a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
MDWD shares declined about 6.5% in premarket trading after the release, slipping to roughly $12.92 from a prior close of $13.82 and positioning the stock toward the lower end of its 52-week range of $11.80 to $19.70. The reaction indicates investors placed greater weight on the sizable revenue miss than on the modest adjusted earnings-per-share beat. That pattern aligns with how many development-stage biotech names are assessed, where focus tends to rest on revenue trends, clinical advancement, and cash runway rather than headline earnings alone. The broader operating loss and ongoing cash burn added to a cautious tone for the balance of 2026.
Forward Outlook and Key Factors to Monitor
MediWound's near-term narrative centers on execution across three areas. First, the Phase III VALUE trial for EscharEx in venous leg ulcers stays the primary focus. Management noted that enrollment of the 216-patient study, run across roughly 40 sites, should wrap by the end of the first quarter of 2027, with top-line results anticipated in mid-2027 following about three months of treatment and data processing.
Second, attention turns to manufacturing expansion. NexoBrid demand continues to outpace capacity, and commercial supply from the expanded facility is slated for the second half of 2027, pending regulatory approval. Third, the revenue outlook carries notable uncertainty linked to funding for a planned U.S.-based manufacturing facility. A meaningful portion of the 2027 revenue guidance of $24 million to $26 million rests on those government discussions, whose timing remains unclear.
On the balance sheet, cash, cash equivalents, and deposits stood at $28.4 million at quarter-end, down from $53.6 million at the end of 2025. A November underwritten public offering that raised $17.25 million in gross proceeds aims to extend the runway through and past the VALUE data readout. As trial spending is expected to ease substantially near completion, the spotlight shifts to clinical milestones, funding clarity, and manufacturing capacity as the main catalysts ahead.
Exploring AI Tools for Deeper Analysis
In my view, incorporating AI-driven screening can add useful perspective when evaluating names like this amid shifting fundamentals and clinical timelines. I find it helpful to cross-check sector peers and technical signals to better frame how the stock might respond to upcoming catalysts. One short example is using an AI-powered tool to scan for comparable setups in the biotech space and monitor volatility patterns around earnings events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDWD's RSI Oscillator recovers from oversold territory
The RSI Indicator for MDWD moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 29 of the 35 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for MDWD crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +10.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDWD advanced for three days, in 183 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where MDWD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDWD as a result. In 72 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for MDWD turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
MDWD moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDWD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
MDWD broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MDWD entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.161) is normal, around the industry mean (3.498). P/E Ratio (-8.906) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.045) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. MDWD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDWD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement